Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07099092 · ClinicalTrials.gov registry record · Early Phase 1

Causal Mechanisms of Odor-Guided Behavior in Humans

A Early Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).

Not yet
Registry status
Early Phase 1
Development phase
80
Enrollment target

NCT07099092: Clinical Trial Early Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).

NCT07099092 is a Early Phase 1 study that has not yet begun recruiting, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 80 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07099092, a Early Phase 1 study, has not yet begun recruiting, sponsored by National Institute on Drug Abuse (NIDA).

NOT YET RECRUITING
Registry status
Early Phase 1
Development phase
80 participants
Enrollment target

Study Summary

Background: Little is known about how different regions of the brain responsible for the human sense of smell guide behaviors. In this study, researchers use a technique called transcranial ultrasound stimulation (TUS) to learn how odors affect the brain and behavior. Objective: To learn more about how the human sense of smell works. Eligibility: Healthy people aged 18 to 45 years who are right-handed. Design: Participants can volunteer for up to 2 different experiments. Each experiment requires 5 visits, each about 1 week apart. Food, alcohol, and caffeine may be limited before visits. At the start of each visit, participants will answer questions about their health and how well they slept. Their sense of smell will be assessed. Some visits may include tasks on a computer: While doing these tasks, participants may be asked to smell different odors, look at pictures, and listen to sounds. They will wear devices to track breathing, blood pressure, pulse, and other body responses to the tasks. Some visits may include TUS: TUS uses ultrasound waves to briefly change brain activity. A gel will be applied to the scalp and hair, and a device will be placed against the participant s head. Participants may feel a tapping, pulling, and/or warm sensation on the skin underneath the device. They may also feel a twitch in their face, neck, arm, or leg muscles. Participants will do tasks before and after TUS. Some visits will include functional magnetic resonance imaging (fMRI) scans. fMRI uses magnet and radio waves to capture images of the activity inside the brain. Participants will lie on a table that slides into a tube. They will perform tasks inside the scanner.

Primary Outcome

Responses on behavioral tasks

Interventions

  • DEVICE TUS PirC
  • DEVICE TUS Amy
  • DEVICE TUS Sham

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2026-07-15
Est. Completion 2035-07-14
Phase Early Phase 1

What is known before NCT07099092 opens enrollment

NCT07099092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher).

The record links to 0 conditions, and to 3 interventions - of which TUS PirC is the first listed.

NCT07099092 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07099092 about?

NCT07099092 is a clinical study titled "Causal Mechanisms of Odor-Guided Behavior in Humans". Background: Little is known about how different regions of the brain responsible for the human sense of smell guide behaviors. In this study, researchers use a technique called transcranial ultrasound stimulation (TUS) to learn how odors affect the brain and behavior. Objective: To learn more abo...

What is the current status of trial NCT07099092?

This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2026-07-15. Estimated completion is 2035-07-14.

What interventions are being tested in trial NCT07099092?

The interventions under investigation include: TUS PirC (DEVICE), TUS Amy (DEVICE), TUS Sham (DEVICE).

Who is sponsoring clinical trial NCT07099092?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07099092's enrollment target sits among peer trials

80 271st of 2000 higher than 1,703 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07099092, the US trial registry maintained by the National Library of Medicine. NCT07099092 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.